Hiv-associeret lipodystrofisyndrom. Diagnostik, praevalens, patogenese og metaboliske komplikationer
Sammanfattning
HIV-associated lipodystrophy syndrome (HALS) is recognised by fat redistribution, most often as fat loss in the face, arms, legs, and buttocks concomitantly with intra-abdominal fat gain. HALS is prevalent in approximately 40% of HIV-infected patients undergoing highly active antiretroviral ther-apy. HALS as associated with insulin resistance and dyslipid-emia. Increasing prevalence of diabetes and of cardiovascular complications is expected. The cause of HALS is esentially unknown. This article discusses the diagnosis, prevalence, metabolic complications, risk factors, and pathogenesis rel-ated to HALS.